A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study

Trial Profile

A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Clostridium infections; Diarrhoea
  • Focus Adverse reactions
  • Acronyms PUNCH-CD
  • Sponsors Rebiotix
  • Most Recent Events

    • 09 May 2017 Results assessing impact of donor for RBX2660 (donor derived microbiota-based drug) on patient outcomes using data from two separate clinical studies (PUNCH CD and PUNCH CD 2), presented at the Digestive Disease Week 2017.
    • 04 May 2017 Results from this trial will be presented at the Digestive Disease Week (DDW) 2017, according to Rebiotix media release.
    • 12 Nov 2015 Results published in the Clinical Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top